Close

Press Releases

AbbVie Announces Positive Phase 3 Data for Atogepant in Migraine Prevention

AbbVie announced that the Phase 3 ADVANCE trial evaluating the investigational medicine atogepant, an orally administered calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) met its primary endpoint of statistically significantly greater reduction in mean monthly migraine days, compared to...

Sanofi and GSK agree with the UK government to supply up to 60 million doses of COVID-19 vaccine

Sanofi and GSK have reached an agreement, subject to final contract, with the UK government for the supply of up to 60 million doses of a COVID-19 vaccine. The vaccine candidate, developed by Sanofi in partnership with GSK, is...

Pfizer and BioNTech Choose Lead mRNA Vaccine Candidate Against COVID-19 and Pivotal Phase Global Study

Pfizer Inc. and BioNTech SEย announced the start of a global (except for China) Phase 2/3 safety and efficacy clinical study to evaluate a single nucleoside-modified messenger RNA (modRNA) candidate from their BNT162 mRNA-based vaccine program against SARS-CoV-2. After extensive review...

Catalent Enters into Strategic Partnership with Editas Medicine to Support Gene Editing Medicine Pipeline

Editas Medicine, Inc., a leading genome editing company, and Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, announced that they have entered into...

PCI Pharma Services Announces Global Expansion of Clinical Trial Services

PCI Pharma Services (PCI), a leading pharmaceutical and biopharmaceutical global outsourcing solutions provider, announced a significant milestone in its global clinical footprint with the creation of a new Clinical Center of Excellence (COE) in Western Europe at its Berlin...

Lonza’s Ibex Dedicate to Support the Commercial Manufacture of Kodiak’s KSI-301

We are committed to supporting Kodiak as they bring their highly innovative, sight-saving treatment option to patients with vision-threatening retinal diseases. Since 2014, we have been partnering with Kodiak to support the supply of KSI-301 drug substance for use...

Dalton Pharma Services Partners with Vido-InterVac to Combat Covid-19

Dalton Pharma Services, a leading North American pharmaceutical cGMP CDMO, is pleased to announce a partnership with the University of Saskatchewanโ€™s Vaccine and Infectious Disease Organizationโ€“International Vaccine Centre (VIDO-InterVac), a global leader in human and animal infectious disease research...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate ยป